AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Theravance Biopharma Inc (NASDAQ:TBPH)
11.35 USD
+0.620 5.778%Sponsored Reports
Loading...
| Previous Close (in USD) | 10.73 |
|---|---|
| Change | +0.620 5.778% |
| 52 W H/L (in USD) | 10.900/7.440 |
| EBITDA (in USD) | -43.972M |
| PE Ratio | -- |
| Volume | 175475 |
| Diluted Eps TTM | -1.18 |
| Total Assets (in USD) | 354.161M |
|---|---|
| Total Liabilities (in USD) | 178.616M |
| Revenue TTM (in USD) | 65.266M |
| Cash (in USD) | 37.797M |
| Market Cap (in USD) | 460.012 M |
| Revenue Per Share TTM | 1.326 |
| Gross Profit TTM (in USD) | 28.018M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
901 Gateway Boulevard, South San Francisco, CA, United States, 94080
650-808-6000
Employees: 97
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Rick E. Winningham M.B.A. | Chairman & CEO | 1960 |
| 2. | Mr. Andrew Asa Hindman M.B.A | Sr. VP & CFO | 1973 |
| 3. | Ms. Rhonda F. Farnum | Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs | 1965 |
| 4. | Dr. Richard A. Graham Ph.D. | Sr. VP of R&D | 1974 |
| 5. | Ms. Gail B. Cohen | VP of Corp. Communications & Investor Relations | NA |
| 6. | Mr. Brett A. Grimaud Esq. | Sr. VP, Gen. Counsel & Sec. | NA |
| 7. | Ms. Stacy L. Pryce | Sr. VP & Chief Strategy Officer | NA |
| 8. | Mr. Aziz Sawaf C.F.A. | Senior VP & CFO | 1982 |
| 9. | Stuart Knight | VP of IT&I & Chief Information Officer | NA |
| 10. | Ms. Gail B. Cohen | Vice President of Corporate Communications & Investor Relations | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.070 1.581% | 68.76 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+2.420 3.640% | 68.9 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+2.740 0.618% | 442.99 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.606 0.500% | 521.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|---|
| Income Before Tax | -44.614M | -49.269M | -92.815M | -199.577M | -286.537M |
| Minority Interest | - | - | - | - | - |
| Net Income | -56.418M | -55.193M | -92.824M | -199.426M | -278.017M |
| Selling General Administrative | 69.174M | 64.995M | 59.073M | 99.296M | 108.661M |
| Gross Profit | 58.367M | 16.803M | 44.757M | 48.025M | -189.096M |
| Reconciled Depreciation | 3.615M | 4.864M | 7.024M | 9.708M | 9.063M |
| Ebit | -47.16M | -46.919M | -86.446M | -256.675M | -300.643M |
| Ebitda | -46.949M | -40.867M | -79.857M | -249.389M | -293.999M |
| Depreciation And Amortization | 0.211M | 6.052M | 6.589M | 7.286M | 6.644M |
| Operating Income | -46.949M | -56.035M | -91.957M | -257.784M | -297.757M |
| Other Operating Expenses | 111.33M | 113.459M | 130.465M | 292.953M | 369.614M |
| Interest Expense | 2.546M | 2.35M | 6.369M | 46.889M | 44.585M |
| Tax Provision | 11.804M | 2.427M | 0.009M | -0.151M | -8.52M |
| Interest Income | 4.881M | 10.991M | 8.545M | 1.109M | 2.831M |
| Net Interest Income | 2.335M | 8.714M | 2.176M | -45.78M | -41.754M |
| Income Tax Expense | 11.804M | 5.924M | 0.009M | -0.151M | -8.52M |
| Total Revenue | 64.381M | 57.424M | 51.346M | 55.311M | 71.857M |
| Total Operating Expenses | 111.33M | 113.459M | 130.465M | 292.953M | 369.614M |
| Cost Of Revenue | 6.014M | 40.621M | 6.589M | 7.286M | 260.953M |
| Total Other Income Expense Net | 2.335M | 6.766M | -0.858M | -7.438M | 11.22M |
| Net Income From Continuing Ops | -56.418M | -60.939M | -92.824M | -199.426M | -278.017M |
| Net Income Applicable To Common Shares | - | - | 872.132M | -199.426M | -278.017M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|---|
| Total Assets | 354.161M | 381.999M | 607.4M | 374.819M | 469.057M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 4.277M | 13.641M | 7.682M | 8.561M | 10.359M |
| Total Liab | 178.616M | 169.004M | 165.6M | 713.392M | 772.808M |
| Total Stockholder Equity | 175.545M | 212.995M | 441.8M | -338.573M | -303.751M |
| Other Current Liab | 7.425M | 24.767M | -1.578M | 37.948M | 76.072M |
| Common Stock | - | - | 0.001M | 0.001M | 0.001M |
| Capital Stock | 0M | 0M | 0.001M | 0.001M | 0.001M |
| Retained Earnings | -965.522M | -909.104M | -853.911M | -1726.043M | -1526.617M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 201.935M | 4.065M | 3.284M |
| Cash | 37.797M | 39.545M | 298.172M | 89.959M | 81.467M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 32.085M | 24.767M | 28.715M | 58.587M | 123.571M |
| Current Deferred Revenue | - | -5.447M | 0.024M | 0.098M | 11.523M |
| Net Debt | 12.023M | 5.691M | -224.05M | 562.116M | 565.589M |
| Short Term Debt | 10.712M | 3.923M | 28.715M | 17.443M | 29.201M |
| Short Long Term Debt | - | - | - | 16.94M | 19.334M |
| Short Long Term Debt Total | 49.82M | 45.236M | 74.122M | 652.075M | 647.056M |
| Other Stockholder Equity | 1141.06M | 1122.164M | 1295.725M | 1387.469M | 1222.818M |
| Property Plant Equipment | - | - | 11.875M | 53.347M | 16.422M |
| Total Current Assets | 161.067M | 133.541M | 353.464M | 249.87M | 393.341M |
| Long Term Investments | - | - | 0M | 67.537M | 12.75M |
| Short Term Investments | 50.553M | 62.881M | 29.312M | 83.506M | 211.474M |
| Net Receivables | 68.44M | 17.474M | 16.785M | 57.599M | 69.667M |
| Long Term Debt | - | - | - | 599.394M | 226.963M |
| Inventory | -68.513M | 0M | 1.513M | 10.245M | 20.374M |
| Accounts Payable | 2.242M | 1.524M | 1.554M | 3.098M | 6.775M |
| Accumulated Other Comprehensive Income | 0.007M | -0.065M | -0.015M | - | 0.047M |
| Non Currrent Assets Other | 157.322M | 202.267M | 201.935M | 4.065M | 3.284M |
| Non Current Assets Total | 193.094M | 248.458M | 253.936M | 124.949M | 75.716M |
| Capital Lease Obligations | 49.82M | 49.159M | 74.122M | 52.681M | 47.22M |
| Long Term Debt Total | - | - | - | 228.035M | 226.963M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|---|
| Investments | 12.284M | 7.141M | 54.872M | 127.894M | 17.273M |
| Total Cashflows From Investing Activities | - | - | 1154.009M | 124.494M | 10.721M |
| Total Cash From Financing Activities | -2.497M | -198.933M | -758.806M | 91.86M | 263.085M |
| Net Income | -56.418M | -55.193M | -92.824M | -199.426M | -278.017M |
| Change In Cash | -1.748M | -258.627M | 208.212M | 8.496M | 23.403M |
| Begin Period Cash Flow | 40.381M | 299.008M | 90.796M | 82.3M | 58.897M |
| End Period Cash Flow | 38.633M | 40.381M | 299.008M | 90.796M | 82.3M |
| Total Cash From Operating Activities | -11.535M | -26.997M | -186.991M | -207.858M | -250.403M |
| Depreciation | 3.615M | 4.256M | 7.024M | 9.708M | 9.063M |
| Other Cashflows From Investing Activities | -2.292M | 1.513M | 1095.134M | 127.9M | 0.064M |
| Dividends Paid | - | - | 0.802M | - | 385.062M |
| Change To Inventory | - | -8.543M | - | -26.39M | -22.525M |
| Sale Purchase Of Stock | -3.104M | -199.551M | -132.28M | -9.061M | -9.749M |
| Other Cashflows From Financing Activities | 0.508M | 0.618M | 5.077M | 3.471M | 764.798M |
| Capital Expenditures | 0.332M | 2.488M | 0.572M | 3.406M | 6.616M |
| Change In Working Capital | 20.355M | -8.34M | 42.35M | -39.584M | -39.462M |
| Other Non Cash Items | 7.093M | 3.702M | -183.275M | 3.86M | -20.427M |
| Free Cash Flow | -11.867M | -29.485M | -187.563M | -211.264M | -257.019M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 1143060 |
| 2. | iShares Russell 2000 ETF | 1 month ago | 878469 |
| 3. | Pictet Biopharmaceutical Mother | 8 months ago | 652300 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 544311 |
| 5. | Fidelity Small Cap Index | 4 months ago | 363334 |
| 6. | iShares Russell 2000 Value ETF | 1 month ago | 348490 |
| 7. | State St Russell Sm/Mid Cp® Indx SL Cl I | 1 month ago | 330210 |
| 8. | iShares Biotechnology ETF | 1 month ago | 288406 |
| 9. | CREF Stock R3 | 2 months ago | 253479 |
| 10. | Macquarie Healthcare I | 2 months ago | 208783 |
| 11. | BlackRock Global Equity Mkt Netrl Instl | 2 months ago | 199344 |
| 12. | Fidelity Extended Market Index | 2 months ago | 192865 |
| 13. | Vanguard Russell 2000 ETF | 1 month ago | 185212 |
| 14. | Schwab US Small-Cap ETF™ | 1 month ago | 170446 |
| 15. | DFA US Small Cap I | 2 months ago | 136608 |
| 16. | State St Russell Sm Cap® Indx SL Cl I | 1 month ago | 134397 |
| 17. | Dimensional US Small Cap ETF | 1 month ago | 118088 |
| 18. | Vanguard Health Care ETF | 1 month ago | 112717 |
| 19. | Dimensional US Core Equity 2 ETF | 1 month ago | 107880 |
| 20. | Schwab Small Cap Index | 1 month ago | 93101 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Madison Avenue Partners, LP | 5 months ago | 9511150 |
| 2. | Weiss Asset Management LP | 5 months ago | 7457060 |
| 3. | Newtyn Management LLC | 5 months ago | 4757403 |
| 4. | BlackRock Inc | 2 months ago | 3451329 |
| 5. | Irenic Capital Management LP | 5 months ago | 2760948 |
| 6. | Vanguard Group Inc | 2 months ago | 2080463 |
| 7. | Park West Asset Management LLC | 2 months ago | 1804244 |
| 8. | Oasis Management Co. Ltd | 2 months ago | 1118935 |
| 9. | State Street Corp | 2 months ago | 1066775 |
| 10. | Camber Capital Management LLC | 5 months ago | 1000000 |
| 11. | Geode Capital Management, LLC | 5 months ago | 862802 |
| 12. | D. E. Shaw & Co LP | 5 months ago | 833943 |
| 13. | Dimensional Fund Advisors, Inc. | 2 months ago | 643838 |
| 14. | Nuveen Asset Management, LLC | 5 months ago | 495727 |
| 15. | Bank of America Corp | 5 months ago | 481475 |
| 16. | Morgan Stanley - Brokerage Accounts | 5 months ago | 392333 |
| 17. | Northern Trust Corp | 5 months ago | 389980 |
| 18. | Citadel Advisors Llc | 5 months ago | 314622 |
| 19. | BNP Paribas Arbitrage, SA | 2 months ago | 296172 |
| 20. | Charles Schwab Investment Management Inc | 2 months ago | 287716 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...